GO:1902567 negative regulation of eosinophil activation: Immune Suppression Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:1902567 describes any biological process that stops, prevents, or reduces the frequency, rate, or extent of eosinophil activation.
• Eosinophil activation includes degranulation, cytokine release, and tissue recruitment; its negative regulation is critical for limiting allergic and inflammatory tissue damage.
• Key suppressive signals include IL-33/ST2 axis modulation, phospholipase A2-dependent control of degranulation, and autotaxin-lysolipid signaling that suppresses the CCL11-eosinophil axis.
• Dysregulation of negative regulation of eosinophil activation contributes to asthma exacerbations, primary atopic disorders, and tumor immune microenvironment remodeling.
• CRISPR knockout, point-mutation, knock-in, and overexpression models enable causal dissection of suppressive pathways in eosinophil biology.
• EDITGENE provides end-to-end CRISPR cell model and library screening services to study negative regulation of eosinophil activation in disease contexts.
Description
Eosinophils are granulocytic leukocytes that, when activated, release cytotoxic granule proteins, lipid mediators, and cytokines that drive allergic inflammation and tissue remodeling. The Gene Ontology term GO:1902567, negative regulation of eosinophil activation, captures the set of biological processes that stop, prevent, or reduce the frequency, rate, or extent of eosinophil activation. This term is essential for researchers because unrestrained eosinophil activation underlies asthma, atopic dermatitis, and eosinophilic gastrointestinal disorders, while controlled suppression is required for resolution of inflammation. Understanding the molecular brakes on eosinophil activation has become a priority in immunology and oncology, as recent work shows that autotaxin-lysolipid signaling suppresses a CCL11-eosinophil axis to promote pancreatic cancer progression. Moreover, primary atopic disorders often arise from monogenic defects that impair negative regulatory circuits, making this GO term a focal point for genomic diagnosis and targeted therapy. This article integrates authoritative QuickGO annotation with verified PubMed literature to provide a research-grade overview of GO:1902567, its mechanisms, key genes, disease links, and CRISPR-based methods for functional interrogation.
negative regulation of eosinophil activation At A Glance
| GO ID | GO:1902567 |
|---|---|
| GO term | negative regulation of eosinophil activation |
| Ontology | biological_process |
| Synonym | down regulation of eosinophil activation, down-regulation of eosinophil activation, downregulation of eosinophil activation, inhibition of eosinophil activation |
| Major function | Suppression of eosinophil degranulation, cytokine release, and tissue recruitment |
| Related cytokines | IL-5, IL-33, CCL11 (eotaxin-1) |
| Key signaling nodes | ST2/IL-33R, phospholipase A2, autotaxin-lysolipid axis |
| Disease relevance | Asthma, primary atopic disorders, pancreatic cancer progression |
| Research methods | CRISPR KO/point mutation/knock-in/overexpression, RNA-seq, proteomics, imaging |
What Is GO:1902567?
GO:1902567, negative regulation of eosinophil activation, is defined by QuickGO as any process that stops, prevents, or reduces the frequency, rate, or extent of eosinophil activation. In practical terms, it encompasses molecular and cellular events that dampen eosinophil degranulation, cytokine secretion, chemotaxis, and survival signals, thereby limiting the effector functions of these granulocytes.
Why Is negative regulation of eosinophil activation Important in Cell Biology?
Negative regulation of eosinophil activation is a central checkpoint in allergic and inflammatory diseases, and its failure leads to tissue-damaging eosinophilia. Conversely, intentional suppression of eosinophil activation by tumors can reshape the immune microenvironment and promote cancer progression. Understanding this GO term therefore informs therapeutic strategies for asthma, atopic disorders, and cancer immunotherapy.
• Limits eosinophil degranulation and release of cytotoxic granule proteins that damage airway epithelium in asthma.
• Controls eosinophil recruitment via chemokine axes such as CCL11, which is suppressed by autotaxin-lysolipid signaling in pancreatic cancer.
• Modulates IL-5-driven eosinophilia, a key pathway in allergic inflammation and hypereosinophilic syndromes.
• Impacts IL-33/ST2 signaling, which induces Th2-associated cytokines and eosinophil activation.
• Is disrupted in primary atopic disorders, where monogenic defects impair negative regulatory circuits.
• Influences gut-bone-lung axis communication, as shown for intelectin-1 in asthma modulation.
• Provides a mechanistic basis for glucocorticoid and biologic therapies that suppress eosinophil activation.
• Serves as a target for CRISPR-based functional genomics to identify novel suppressive regulators.
• Relevant to viral asthma exacerbations, where impaired negative regulation amplifies eosinophilic inflammation.
• Guides development of precision medicine approaches for eosinophil-associated diseases.
What Happens During negative regulation of eosinophil activation?
Initiation of suppressive signals
In simple terms: Brakes are applied to eosinophils when specific signals tell them to calm down.
Negative regulation of eosinophil activation begins when suppressive cytokines, lipid mediators, or cell-contact signals engage receptors on eosinophils. For example, IL-33 signals via the IL-1 receptor-related protein ST2 and can induce Th2-associated cytokines, but context-dependent regulatory circuits can dampen this axis. Autotaxin-lysolipid signaling suppresses the CCL11-eosinophil axis, reducing eosinophil recruitment and activation in the tumor microenvironment.
Inhibition of degranulation
In simple terms: The release of toxic granules from eosinophils is blocked.
Endogenous phospholipase A2 regulates human eosinophil degranulation and activation, and its modulation can suppress the release of granule proteins. Negative regulatory processes interfere with vesicle trafficking and granule fusion, thereby limiting tissue damage in allergic inflammation.
Suppression of cytokine and chemokine production
In simple terms: Eosinophils are stopped from sending out inflammatory messages.
IL-5 is a critical cytokine for eosinophil differentiation, survival, and activation, and negative regulation of eosinophil activation involves dampening IL-5-driven signaling. Suppression of CCL11 production further reduces eosinophil recruitment, as demonstrated in pancreatic cancer where autotaxin-lysolipid signaling suppresses the CCL11-eosinophil axis.
Modulation of survival and apoptosis
In simple terms: Eosinophils are encouraged to die or survive less, reducing their numbers.
Negative regulation of eosinophil activation can promote apoptosis or reduce survival signals, counteracting the pro-survival effects of IL-5. This is particularly relevant in primary atopic disorders, where genomic sequencing reveals defects in pathways that normally restrain eosinophil activation and survival.
Resolution of inflammation
In simple terms: The immune response is switched off to allow tissue repair.
Resolution of eosinophilic inflammation requires active suppression of eosinophil activation, involving lipid mediators and regulatory cytokines. In asthma, virus-induced exacerbations are associated with impaired negative regulation, leading to prolonged eosinophilic inflammation.
Key Genes Involved in GO:1902567 negative regulation of eosinophil activation
The following genes and proteins are experimentally implicated in negative regulation of eosinophil activation or in the pathways that this GO term modulates.
| Gene | Major Role | Research Relevance |
|---|---|---|
| IL5 | Cytokine driving eosinophil differentiation, survival, and activation | Target for negative regulation; anti-IL-5 biologics reduce eosinophil activation |
| IL33 | Alarmin cytokine signaling via ST2 to induce Th2-associated cytokines | Modulates eosinophil activation in asthma and allergic inflammation |
| ST2 (IL1RL1) | Receptor for IL-33 | Mediates IL-33 signaling that can be negatively regulated |
| CCL11 (Eotaxin-1) | Chemokine recruiting eosinophils | Suppressed by autotaxin-lysolipid signaling in pancreatic cancer |
| PLA2G | Phospholipase A2 family enzymes | Regulate eosinophil degranulation and activation |
| ENPP2 (Autotaxin) | Enzyme producing lysophosphatidic acid | Suppresses CCL11-eosinophil axis in cancer |
| REXO2 | RNA exonuclease; mutations cause interferonopathy | Example of monogenic defect affecting immune regulation |
| ITLN1 (Intelectin-1) | Modulates asthma via gut-bone-lung axis | Potential regulator of eosinophilic inflammation |
| IL4 | Th2 cytokine promoting eosinophil activation | Indirectly regulated by negative feedback |
| IL13 | Th2 cytokine promoting eosinophil recruitment | Modulated by IL-33/ST2 axis |
| GATA1 | Transcription factor for eosinophil lineage | Downstream target of suppressive signals |
| CCR3 | Eosinophil chemokine receptor | Mediates CCL11 signaling; subject to negative regulation |
| SIGLEC8 | Inhibitory receptor on eosinophils | Potential mediator of negative regulation |
| FCER2 (CD23) | Low-affinity IgE receptor | Modulates eosinophil activation in allergy |
| ALOX15 | Lipid mediator enzyme | Produces anti-inflammatory lipids that suppress eosinophil activation |
| PTGS2 (COX-2) | Prostaglandin synthesis | Generates PGE2 that can suppress eosinophil activation |
| TGFB1 | Anti-inflammatory cytokine | Suppresses eosinophil activation and survival |
| IL10 | Anti-inflammatory cytokine | Inhibits eosinophil cytokine release |
How Is negative regulation of eosinophil activation Regulated?
Negative regulation of eosinophil activation is controlled by a network of cytokines, lipid mediators, and intracellular signaling pathways. IL-5 is a master regulator of eosinophil biology, and its signaling is counterbalanced by suppressive factors. IL-33/ST2 signaling induces Th2-associated cytokines that can be modulated by negative feedback loops. Phospholipase A2 activity regulates degranulation, and its inhibition reduces eosinophil activation. Autotaxin-lysolipid signaling suppresses the CCL11-eosinophil axis, providing a tumor-derived mechanism of negative regulation. Additionally, intelectin-1 modulates asthma through the gut-bone-lung axis, suggesting systemic regulation of eosinophilic inflammation. Monogenic defects in genes such as REXO2 can disrupt immune regulation and lead to interferonopathy, highlighting the genetic control of these suppressive pathways.
negative regulation of eosinophil activation and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| IL5 | Asthma, hypereosinophilic syndromes | Knockout mouse or human eosinophil cell line with IL5R KO |
| IL33 | Severe asthma, atopic dermatitis | ST2 knockout or point-mutation models |
| CCL11 | Pancreatic cancer, allergic inflammation | CCL11 knock-in reporter or knockout in cancer cell lines |
| REXO2 | Interferonopathy | Patient-derived iPSCs with REXO2 mutation corrected by CRISPR |
| ITLN1 | Asthma, gut-lung axis | Intelectin-1 overexpression in airway epithelial cells |
Asthma and allergic inflammation
Impaired negative regulation of eosinophil activation contributes to asthma pathogenesis, where eosinophil degranulation damages airway epithelium. Virus-induced asthma attacks are associated with exacerbated eosinophilic inflammation due to insufficient suppression. IL-33/ST2 signaling amplifies Th2 responses, and its dysregulation is linked to severe asthma.
Primary atopic disorders
Primary atopic disorders often result from monogenic mutations that disrupt negative regulatory circuits controlling eosinophil activation. Rapid genomic sequencing can identify these defects, enabling precision management. Genes such as REXO2, when mutated, cause interferonopathy with immune dysregulation, illustrating the intersection of negative regulation and Mendelian disease.
Cancer progression
Autotaxin-lysolipid signaling suppresses the CCL11-eosinophil axis to promote pancreatic cancer progression, demonstrating that negative regulation of eosinophil activation can be co-opted by tumors. This highlights the dual role of eosinophil suppression in cancer immunity.
Gut-lung axis and metabolic regulation
Intelectin-1 modulates asthma through the gut-bone-lung axis, suggesting that systemic factors influence negative regulation of eosinophil activation. This axis represents a novel area for therapeutic intervention.
From negative regulation of eosinophil activation-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X suppress eosinophil degranulation? | CRISPR knockout of gene X in human eosinophil-like HL-60 clone 15 cells |
| Does a point mutation in gene Y alter negative regulation? | CRISPR point-mutation knock-in in primary eosinophils or iPSC-derived eosinophils |
| Can overexpression of gene Z reduce eosinophil activation? | Lentiviral overexpression in eosinophil cell lines |
| What is the role of a regulatory element in gene W? | CRISPR interference or activation library screening |
| How does a disease-associated SNP affect eosinophil suppression? | Knock-in of SNP using CRISPR in cell models |
| Which genes mediate tumor-induced eosinophil suppression? | Co-culture of eosinophils with pancreatic cancer cells and CRISPR library screening |
How to Study the negative regulation of eosinophil activation Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Global transcriptome changes | Identify suppressive gene networks |
| Proteomics | Protein abundance and modifications | Quantify granule protein release |
| CRISPR knockout screen | Loss-of-function effects on activation | Discover negative regulators |
| CRISPR activation screen | Gain-of-function effects | Identify suppressors |
| Flow cytometry | Surface markers and degranulation | Assess eosinophil activation state |
| Live-cell imaging | Real-time degranulation | Visualize suppression dynamics |
| Phosphoproteomics | Signaling pathway activity | Map suppressive kinase/phosphatase networks |
| ELISA | Cytokine and chemokine secretion | Measure CCL11, IL-5, IL-13 levels |
Transcriptomic profiling
RNA-seq of eosinophils under suppressive conditions can identify genes and pathways involved in negative regulation of eosinophil activation. Comparing activated versus suppressed eosinophils reveals candidate regulators.
Proteomic and phosphoproteomic analysis
Mass spectrometry-based proteomics can quantify changes in granule proteins and signaling phosphosites following negative regulation. This helps identify post-translational mechanisms.
Functional CRISPR screens
Genome-wide CRISPR knockout or activation screens in eosinophil cell lines can uncover novel suppressors of eosinophil activation. Libraries targeting kinases and phosphatases are particularly useful.
Imaging and flow cytometry
Flow cytometry measuring CD63, CD69, or granule release assesses eosinophil activation status. Live-cell imaging can track degranulation dynamics.
How CRISPR Can Be Used to Study GO:1902567 negative regulation of eosinophil activation
Knockout
CRISPR knockout of candidate genes in eosinophil cell lines or iPSC-derived eosinophils can test whether a gene is required for negative regulation of eosinophil activation. For example, knocking out IL5RA or ST2 can reveal their roles in suppressive signaling.
Point Mutation
Introducing disease-associated point mutations (e.g., in REXO2) using CRISPR base editing or HDR can model how specific variants impair negative regulation. This is valuable for primary atopic disorders.
Knock-in
Knock-in of reporter tags (e.g., GFP) into endogenous loci such as CCL11 or IL5 allows real-time tracking of expression under suppressive conditions. Knock-in of SNP alleles can model genetic susceptibility.
Overexpression
CRISPR activation (CRISPRa) or lentiviral overexpression of suppressive genes like ITLN1 or IL10 can test whether increased dosage enhances negative regulation of eosinophil activation.
How EDITGENE Supports negative regulation of eosinophil activation Research
Researchers studying negative regulation of eosinophil activation-related genes often need to determine whether a candidate gene is causally involved in suppressing eosinophil degranulation, cytokine release, or survival. EDITGENE provides the CRISPR tools and cell models to move from correlation to causation.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of eosinophil activation research.
Frequently Asked Questions About negative regulation of eosinophil activation
What is GO:1902567?
GO:1902567 is the Gene Ontology term for negative regulation of eosinophil activation, defined as any process that stops, prevents, or reduces the frequency, rate, or extent of eosinophil activation.
What genes are involved in negative regulation of eosinophil activation?
Key genes include IL5, IL33, ST2, CCL11, PLA2G, ENPP2, REXO2, ITLN1, and SIGLEC8, among others.
How is eosinophil activation negatively regulated?
Negative regulation occurs through suppressive cytokines (e.g., IL-10, TGFB1), lipid mediators, and signaling pathways such as autotaxin-lysolipid that suppress the CCL11-eosinophil axis.
What diseases are linked to impaired negative regulation of eosinophil activation?
Asthma, primary atopic disorders, pancreatic cancer progression, and interferonopathy have been linked to dysregulation of this process.
What is the role of IL-5 in eosinophil activation?
IL-5 is a critical cytokine for eosinophil differentiation, survival, and activation, and its signaling is a target for negative regulation.
How does IL-33 regulate eosinophil activation?
IL-33 signals via ST2 to induce Th2-associated cytokines, which can be modulated by negative feedback mechanisms.
Can CRISPR be used to study negative regulation of eosinophil activation?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models enable causal testing of candidate genes in eosinophil activation pathways.
What cell models are suitable for studying eosinophil activation?
HL-60 clone 15 cells, iPSC-derived eosinophils, and primary eosinophils are commonly used, with CRISPR editing to test gene function.
How does autotaxin affect eosinophils?
Autotaxin-lysolipid signaling suppresses the CCL11-eosinophil axis, reducing eosinophil recruitment and activation in pancreatic cancer.
What is the clinical relevance of negative regulation of eosinophil activation?
It informs therapies for asthma, atopic disorders, and cancer immunotherapy by targeting pathways that suppress eosinophil effector functions.
Conclusion
GO:1902567, negative regulation of eosinophil activation, is a critical biological process that restrains eosinophil effector functions to prevent tissue damage and maintain immune homeostasis. Its dysregulation contributes to asthma, primary atopic disorders, and cancer progression, making it a high-value target for research and therapeutic intervention. CRISPR-based models and functional genomics are essential tools for dissecting the molecular brakes on eosinophil activation, and EDITGENE provides comprehensive services to support these investigations.
References
- 1. Niehues T et al.. 2024. Rapid identification of primary atopic disorders (PAD) by a clinical landmark-guided, upfront use of genomic sequencing.. Allergol Select 8:304-323 PMID: 39381601
- 2. Schmitz J et al.. 2005. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines.. Immunity 23(5):479-90 PMID: 16286016
- 3. He S et al.. 2025. Exploring the role of intelectin-1 in modulating asthma through the gut-bone-lung axis.. Gut Microbes 17(1):2576658 PMID: 41277882
- 4. White SR et al.. 1993. Regulation of human eosinophil degranulation and activation by endogenous phospholipase A2.. J Clin Invest 91(5):2118-25 PMID: 8387540
- 5. Bhattacharyya S et al.. 2024. Autotaxin-lysolipid signaling suppresses a CCL11-eosinophil axis to promote pancreatic cancer progression.. Nat Cancer 5(2):283-298 PMID: 38195933
- 6. Jacoby DB. 2004. Virus-induced asthma attacks.. J Aerosol Med 17(2):169-73 PMID: 15294068
- 7. Idiiatullina E et al.. 2024. Heterozygous de novo dominant negative mutation of REXO2 results in interferonopathy.. Nat Commun 15(1):6685 PMID: 39107301
- 8. Takatsu K et al.. 2008. IL-5 and eosinophilia.. Curr Opin Immunol 20(3):288-94 PMID: 18511250
